Xenetic Biosciences, Inc. (XBIO) — Institutional Holders, Q2 2026
8 institutional investment managers reported a XBIO position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $442.8K. Every filer is listed below, ranked by position value. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
XBIO in Q2 2026: what funds did
Funds that filed a 13F for both Q1 2026 and Q2 2026, by what they did with the common stock. Share counts are adjusted for any split between the two quarters; dollar figures are the change in shares at this quarter’s price.
New positions
2
Added to
1
Trimmed
3
Sold out
0
Biggest buyers
- VANGUARD CAPITAL MANAGEMENTAdded · +5,950 sh+$17.3K
- SBI Securities , Ltd.New · +1,000 sh+$2.9K
- MORGAN STANLEYNew · +150 sh+$437.00
Biggest sellers
- RENAISSANCE TECHNOLOGIESTrimmed · -20,000 sh-$58.2K
- GEODE CAPITAL MANAGEMENTTrimmed · -4,018 sh-$11.7K
- Tower Research Capital (TRC)Trimmed · -110 sh-$320.00
XBIO 13F holders ranked 1–8 of 8
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q1 2026 |
|---|---|---|---|---|---|
| 1 | RENAISSANCE TECHNOLOGIES#1 · 117,440 sh | 117,440 | $341.8K | <0.01% | -14.6% |
| 2 | GEODE CAPITAL MANAGEMENT#2 · 17,423 sh | 17,423 | $50.7K | 0.00% | -18.7% |
| 3 | VANGUARD CAPITAL MANAGEMENT#3 · 12,681 sh | 12,681 | $36.9K | 0.00% | +88.4% |
| 4 | JTC Employer Solutions Trusteee Ltd#4 · 2,700 sh | 2,700 | $8.0K | <0.01% | 0.0% |
| 5 | SBI Securities , Ltd.#5 · 1,000 sh | 1,000 | $2.9K | — | New |
| 6 | Tower Research Capital (TRC)#6 · 696 sh | 696 | $2.0K | 0.00% | -13.6% |
| 7 | MORGAN STANLEY#7 · 150 sh | 150 | $437.00 | 0.00% | New |
| 8 | Darwin Wealth Management#8 · 2 sh | 2 | $5.00 | 0.00% | 0.0% |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.